Objective: Previous studies have shown that sequential exposure to estrogen and progesterone or medroxyprogesterone acetate (MPA) stimulates vascularization and promotes the progression of BT-474 and T47-D human breast cancer cell xenografts in nude mice (Liang et al, Cancer Res 2007, 67:9929). In this follow-up study, the effects of progesterone, MPA, norgestrel (N-EL), and norethindrone (N-ONE) on BT-474 xenograft tumors were compared in the context of several different hormonal environments. N-EL and N-ONE were included in the study because synthetic progestins vary considerably in their biological effects and the effects of these two progestins on the growth of human tumor xenografts are not known.
R ecent studies reported the development of a mouse model for studying the effect of progestins on the growth of breast cancer xenograft tumors in the context of different hormonal environments. 1 In this model, nude mice are sequentially implanted with estradiol before inoculation with tumor cells followed by implantation with progestin pellets. Estradiol supplementation supports a short burst of tumor cell growth, followed by regression and tumor cell senescence and/or apoptosis. However, supplementation with progesterone or medroxyprogesterone acetate (MPA) rescues tumor growth, thus providing a good model in which to examine how the hormonal environment modulates tumor growth and progression. Here, this model is further developed to compare the effects of clinically relevant progestins that are common in clinical use.
Progestins, which are widely administered to postmenopausal women in the context of hormone therapy (HT), prevent estrogen-induced proliferation of uterine cells, which may play a role in endometrial abnormalities including endometrial cancer. 2, 3 However, epidemiological studies suggest that progestin-containing HT may have the adverse effect of increasing breast cancer risk. 4<6 Our experimental data, as described above, are consistent with this epidemiological finding, namely, that progesterone and MPA, a synthetic progestin, induce the progression of p53-deficient, but not p53-proficient, human tumor xenografts (from MCF-7 cells) in nude mice. 1 The goal of this study was to compare the effects of commonly used progestins, which vary in their biological properties, 7<10 on xenograft tumor growth in intact and ovarectomized nude mice. Two androgenic progestins, norgestrel (N-EL) and norethindrone (N-ONE), as well as MPA, were used in this study. Before inoculation, hormone pellets were administered either sequentially or simultaneously. Animals were inoculated with estrogen-and progesterone-receptorpositive and p53-deficient BT-474 breast cancer cells to establish xenografts, and tumor size, expression of vascular endothelial growth factor (VEGF), and tumor vascularity were monitored over time. MPA was included in some experiments as a reference compound because it is the most commonly used progestin in HT, and we have previously documented that MPA increases the proliferation of BT-474 cells in vivo. 1 Exposure of ovariectomized mice to MPA mimics the hormonal environment of HT-treated postmenopausal women.
METHODS

Cell lines and culture
BT-474 breast cancer cells, which contain both estrogen and progesterone receptors (PRs), were obtained from ATCC (Manassas, VA). Cells were maintained in phenol red-free Dulbecco's modified Eagle's medium (DMEM)/F12 medium (Invitrogen Corporation & Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS) in 100 Â 20 mm tissue culture dishes. Cells were harvested using 0.05% trypsin-EDTA (Invitrogen Corporation & Life Technologies).
Hormone pellets
Sixty-day release pellets containing 17A-estradiol (1.7 mg), progesterone (10 mg), MPA (10 mg), N-EL (10 mg), N-ONE (10 mg), or placebo were from Innovative Research of America (Sarasota, FL). After implantation, the steady-state blood levels of the injected compounds reach 2 to 10 ng/mL (Innovative Research).
Progestin-dependent growth of BT-474 human breast xenografts
Intact and ovariectomized female athymic nu/nu mice, 5 to 6 weeks old (18-22 g ), were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN). Mice were housed in a laminar airflow cabinet under specific pathogen-free conditions. All facilities were approved by the American Association for Accreditation of Laboratory Animal Care in accordance with the current federal regulations and standards, and all procedures were approved by an institutional animal care and use committee. Nude mice were inoculated with 17A-estradiol pellets 48 hours before implantation of BT-474 cells. Cells were harvested by trypsinization and were washed twice with DMEM/F12 medium. Cell pellets (1 Â 10 7 cells) were resuspended in 0.15 mL DMEM/F12 medium and injected subcutaneously into the left and right flanks of each mouse (0.15 mL/ injection). Between three and six mice were used for each group, resulting in 6 to 12 tumors in each treatment group, as indicated by n in the figures. Tumor size was measured every 3 days using a digital caliper, and tumor volume was calculated using the formula (L Â W Â H) Â P/6 as previously described. 1, 11 Tumors began to regress after reaching 60 to 100 mm 3 in size (approximately 6-10 d). When tumor volume had decreased by approximately 50%, mice were inoculated with placebo or progestin pellets. This is referred to as the sequential protocol. In some experiments, estrogen and progestin or estrogen and placebo pellets were implanted at the same time, that is, 48 hours before tumor cell inoculation. This is referred to as the combined protocol. Throughout each study, animal weight and behavior were monitored as an index of toxicity. At the end of the treatment period (between days 50 and 60, as indicated in the figures), animals were killed and tumors were harvested and weighed. Fresh tumor tissue was immediately placed in 4% paraformaldehyde for immunohistochemical analysis.
Immunohistochemical assays
Tumor tissue was fixed overnight in 4% paraformaldehyde, followed by paraffin infiltration and embedding. Fivemicrometer sections were mounted onto ProbeOn Plus microscope slides (Fisher Scientific Inc., Pittsburgh, PA), stained with hematoxylin-eosin, and examined for cellularity by light microscopy. Sections were dewaxed in xylene, rehydrated through graded concentrations of ethanol, and rinsed in distilled water. Sections were subjected to heat-induced epitope retrieval in 10 mM citrate buffer (pH 6.0) for 30 minutes and then cooled to room temperature before treatment with 3% hydrogen peroxide in absolute methanol (to inactivate endogenous peroxidase activity). Sections were then washed three times with phosphate-buffered saline, incubated in blocking buffer with 5% bovine serum albumin for 20 minutes, and probed for 60 minutes at room temperature with one of the following antibodies: VEGF (1:200 dilution of a rabbit anti-VEGF polyclonal antibody [sc-152]; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and CD34 (1:25 dilution of a rat monoclonal anti-CD34 [ab8158-100]; Abcam, Inc., Cambridge, MA). Sections were then washed and sequentially incubated with a secondary antibody. VEGF-labeled sections were incubated for 30 minutes with EnVision+, a horseradish peroxidaseYlabeled polymer conjugated to antirabbit antibodies (DAKO). Sections probed with anti-CD34 were incubated for 30 minutes with a biotinylated rabbit antirat IgG (DAKO) and, after a wash, with a streptavidin-linked horseradish peroxidase product (DAKO) for another 30 minutes at room temperature. Bound antibodies were visualized after incubation with 3,3 ¶-diaminobenzidine solution (0.05% with 0.015% H 2 O 2 in phosphate-buffered saline; DAKO) or NovaRED substrate (Vector Laboratories, Inc., Burlingame, CA) for 3 to 5 minutes. Sections were counterstained with Mayer's hematoxylin, dehydrated, cleared, and cover slipped for microscopic examination.
The distribution of immunolabeled cells in histological sections of tumors was determined by use of a morphometric software (FoveaPro 3.0, Reindeer Graphics, copyright 2005) on images photographed at Â20 magnification. There were 9 to 12 images from three to five tumors per treatment group that were analyzed. VEGF distribution was determined on all cells in each tumor image. Results are expressed as area in square pixels.
For blood vessel enumeration, CD34-labeled sections from three to four tumors per treatment group were photographed at Â20 magnification. Investigators performing this determination were blinded to treatment group assignments. The total number of vessels was counted in three to four fields from each tumor section (three to four tumors; 15 sections in total). Vessel density was calculated using vessel number per field and plotted as mean T SEM. Data were analyzed using analysis of variance (ANOVA), and P G 0.05 was considered significant.
Lymph node metastasis
Inguinal lymph nodes were collected from the nude mice at the end of the experiment and were analyzed by one of us (C.B.W.) for the presence of tumor cells after hematoxylineosin staining. The investigator performing this determination was blinded to treatment group assignments. Tumor cells were identified as cohesive, pleomorphic, polygonal to spindle-shaped cells with large vesicular nuclei and moderate to abundant cytoplasm. Immunohistochemical labeling of MHC-1 (anti-MHC-1, sc-25619; Santa Cruz Biotechnology, Inc.) on tumor cells was performed on a subset of tissues to verify identity of the cells (data not shown).
Statistical analysis
Statistical significance was tested with one-way ANOVA using SigmaStat Software version 3.5 (Sigstat Software Inc., Richmond, CA). For ANOVA, the assumption of ANOVA was examined and a nonparametric measure based on ranks was used, as needed. Values are reported as mean T SEM. When ANOVA indicated a significant effect (F ratio, P G 0.05), the Student-Newman-Keuls multirange test was used to compare the means of individual groups. When normality using the Student-Newman-Keuls test failed, significance was determined by the Kruskal-Wallis test (one-way ANOVA by ranks) with the Dunn test. A test to determine the differences in the ability of progestins to increase lymph node metastasis was conducted using logistic ANOVAs, performed using the GENMOD procedure in the SAS program (Cary, NC).
RESULTS
Synthetic progestins rescue the growth of BT-474 xenografts: sequential protocol
The goal of this study was to compare the effects of N-EL, N-ONE, and MPA on the growth of BT-474 tumor xenografts in nude mice. Figure 1A shows the change in tumor size over a 50-day treatment period in animals implanted sequentially with estrogen and N-EL or N-ONE hormone pellets. In animals implanted only with an estrogen pellet, tumors regressed from 6 to 10 days after injection. In contrast, injection with N-EL or N-ONE pellets at day 8 rescued regressing tumors and promoted continued increase in the size of BT-474 xenograft tumors. Representative tumor size and morphology are shown in Fig. 1B . After dosing with N-EL or N-ONE, tumor size and vascularization increased significantly. Average animal weights per treatment group over the course of the experiment are shown in Fig. 1C . Progestin treatment did not reduce animal weight significantly due to toxicity. Thus, treatment of BT-474 xenografts with N-EL and N-ONE led to progression of tumor growth, as was observed with MPA in our previous study. 1 Synthetic progestins rescue the growth of BT-474 xenografts: combined protocol
The effect of a different hormonal environment on tumor growth was tested by coinjecting mice with estradiol and progesterone before tumor cell inoculation. This combined treatment protocol was compared with the sequential treatment protocol, and the results are shown in Fig. 2A . The results show that sequential or combined exposure to estrogen and progesterone promotes the growth of BT-474 xenograft tumors to a similar extent. Similar results were obtained using the combined treatment protocol, when MPA or N-EL was substituted for progesterone (Fig. 2C) . Animal weight did not vary significantly between any treatment groups (Figs. 2B and D) .
MPA enhances BT-474 tumor xenografts in ovariectomized nude mice
The effect of sequential or combined exposure to estrogen and MPA was also examined in ovariectomized nude mice. The results show that MPA promotes the growth of BT-474 xenografts in ovariectomized nude mice, independent of the exposure protocol used in the experiment (Fig. 3A) . Animal   FIG. 1 . Synthetic progestins rescue the growth of BT-474 xenograft tumors: sequential protocol. A: Cells were injected into E 2 -supplemented intact nude mice (as described in BMethods[) followed by implantation of an N-EL or N-ONE pellet (arrow). Tumor size was monitored for 50 days, as indicated. B: Representative tumors from each treatment group are shown. C: Average body weight was calculated for each treatment group at the indicated time points. Five animals were used, and n represents the number of tumors in each group. *P G 0.05, significantly different from the E 2 group (one-way ANOVA, StudentNewman-Keuls test); **P G 0.05, significantly different from the E 2 group (one-way ANOVA, Kruskal-Wallis test). Significance values apply to both the N-EL and N-ONE groups. E 2 , estradiol; N-EL, norgestrel; N-ONE, norethindrone; ANOVA, analysis of variance.
weight was not adversely affected by hormone treatment during this experiment (Fig. 3B) .
Synthetic progestins increase VEGF and tumor blood vessel density
Previous in vitro and in vivo studies show that progestins induce VEGF and stimulate tumor vascularization.
12<14
Therefore, the effect of N-EL and N-ONE on VEGF expression and vascularization was examined in the experimental system used here. The results (Fig. 4A) showed that VEGF expression was twofold to fourfold higher in tumors exposed to estrogen plus MPA, N-EL, or N-ONE than in tumors exposed only to estrogen. Higher VEGF expression is expected to correlate with increased density of blood vessels and increased tumor vascularization. This expectation was verified by immunohistochemical quantification of CD34, an indictor of blood vessel density (Fig. 4B) . The results show a significantly higher expression of CD34 in tumors exposed to estrogen plus MPA, N-EL, or N-ONE than in tumors exposed only to estrogen.
Synthetic progestins increase metastasis of tumor cells to lymph nodes
Because there have been suggestions of increased progestin-dependent metastasis in various models, 15, 16 we isolated inguinal nodes from the animals shown in Fig. 2C and examined these for the presence of tumor cells. N-EL treatment significantly increased the frequency of tumor metastasis when compared with controls ( Fig. 5 ; P G 0.01). Although MPA increased lymph node infiltration of tumor cells, this did not reach statistical significance compared with controls (Fig. 5) . However, based on the differences of least squares means, the odds of MPA treatment increasing metastatic growth was 3.33 times greater than that of the controls, and N-EL increased metastatic growth eight times compared with MPA.
DISCUSSION
The role of progestins in the development of human breast cancer is controversial. Several recent clinical trials and BT-474 cells were injected into estrogensupplemented intact nude mice as described in BMethods,[ and tumor growth was monitored. A P pellet (arrow) was implanted on day 8 (red arrow; E 2 + P-L) or coimplanted with E 2 48 hours before injection with tumor cells (green arrow; E 2 + P-E). *P G 0.05, significantly different from the E 2 group (one-way ANOVA, Student-Newman-Keuls test); **P G 0.05, significantly different from the E 2 group (one-way ANOVA, Kruskal-Wallis test). Significance values apply to both the P-L and P-E groups. B: Average body weight was calculated for each treatment group shown in panel A at the indicated time points. C: MPA or N-EL pellets (arrow) were coimplanted with E 2 48 hours before injection with tumor cells (arrow). *P G 0.05, significantly different from the E 2 group (one-way ANOVA, Student-Newman-Keuls test). D: Average body weight was calculated for each treatment group shown in panel C at the indicated time points. P, progesterone; E 2 , estradiol; ANOVA, analysis of variance; MPA, medroxyprogesterone acetate; N-EL, norgestrel.
clinical studies suggest that the risk of breast cancer is higher in postmenopausal women exposed to estrogen/progestincontaining HT than in those taking estrogen alone or placebo. 4<6 These studies have led to a significant decrease in the use of HT, including those involving progestins, among postmenopausal women. 17 Although MPA is the most widely used progestin in HT and contraception, other progestins, including N-EL and N-ONE, are also used. 18, 19 These progestins are thought to promote uterine cell differentiation, which antagonizes the proliferative effects of estrogens in the uterus. Although the exact role of progestins in the human breast is not known, a number of reports suggest that they play a pro-proliferative, antiapoptotic role in both human and rodent mammary glands.
1,20<25
Tumors appear rapidly in postmenopausal women exposed to estrogen/progestin-containing HT, 4 suggesting that exposure to progestins promotes the proliferation of latent tumor cells within breast tissue. 1, 6, 15 In cell culture and in vivo models, progestins induce VEGF expression in PR-positive/ p53-deficient tumor cells, 12, 13 which could further stimulate tumor cell growth via a paracrine mechanism. 26 In a mouse model of human tumor cellYinduced xenografts, the elaboration of progestin-induced VEGF was shown to be derived from the injected tumor cells and not stromal mouse cells because the induced VEGF was targeted by an antibody to human (not murine) VEGF. 1 Because of the possibility of different synthetic progestins having varying effects on breast tumor growth, 8<10 this study compared the effects of two commonly used progestins, N-EL and N-ONE, on human breast cancer cell xenografts in nude mice. We used Her/2-neu p53-deficient BT-474 cells for this study because these cells grow aggressively and secrete VEGF in response to exposure to progestins. 1 We have previously shown that RU-486, an antiprogestin, arrests progestin-dependent breast cancer cell progression, demonstrating the involvement of PRs.
1 Both N-EL and N-ONE are as effective as MPA in promoting the growth of human breast cancer xenograft tumors in nude mice (Fig. 1A and B) . Not surprisingly, tumors exposed to treatment regimens containing a synthetic progestin and estrogen secrete higher levels of VEGF and express higher levels of CD34 than do tumors exposed to estrogen alone, suggesting that all three progestins promote tumor vascularization (Figs. 4 and 5) .
In this study, the ability of progestins to rescue the growth of regressing BT-474 xenograft tumors was determined, using two different hormone exposure protocols. In initial studies, progestin exposure was initiated after tumor regression began (ie, approximately 6 d after tumor cell inoculation). However, a different hormonal environment, generated by coimplantation of estrogen and progestin pellets before inoculation with tumor cells, was equally effective in supporting tumor growth. Thus, in both of these hormonal environments, tumors are capable of recruiting components of extracellular matrix and stromal cells, forming blood vessels, and proliferating at a sufficient rate to support tumor growth. We believe that progestins play an active role in this process, at least in part by stimulating stromal cell functions in the vicinity of the tumor, as has been suggested by others. 27 In addition, it has also been suggested that progestins may influence the epithelial-mesenchymal transition without having a direct effect on tumor cell proliferation. 28 Both these possibilities will be examined further in future studies.
This study also shows that MPA promotes the growth of BT-474 xenografts in ovariectomized nude mice, independent of the exposure protocol used in the experiment. Thus, it is improbable that intact and/or functional ovaries play a role in tumor progression in this experimental model. However, progestin-induced expression and secretion of VEGF by tumor epithelial cells is likely to be required for tumor growth and progression in this model. Interestingly, our study demonstrated that progestins can increase the metastasis of breast cancer cells to the lymph node. Although we did not detect significant differences in increased VEGF levels and increased numbers of blood vessels in response to the different progestins (Fig. 4) ) . Thus, the increased infiltration of tumor cells observed with this particular progestin could arise as a consequence of a more aggressive growth of BT-474 tumors. It is known that progestins increase the invasiveness of tumor cells, 7 and it may be that N-EL is more potent than MPA in its ability to induce such an effect, although this remains to be established. Further studies are required to determine the role played by PR in promoting metastasis. With this in mind, we will use this model together with anti-progestins such as RU-486 to ascertain whether increased metastasis is PR dependent.
CONCLUSIONS
In conclusion, this study shows that several clinically relevant progestins promote the growth of human breast cancer cells as xenograft tumors in nude mice. These synthetic progestins, which are administered widely as components of HT and oral contraception, could exert similar 29<31 Future studies should also examine the effect of progestins in the context of orthotopic cancer models in the mouse or other animal model systems.
FIG. 5.
Incidence of lymph node metastasis in MPA-and N-ELstimulated BT-474 xenografts in nude mice. Nude mice were implanted with an E 2 and progestin pellet and inoculated with BT-474 cells as described in Fig. 2 . Inguinal lymph glands were collected at the end of the experiment (day 57), and the percentage of lymph nodes infiltrated with tumor cells was quantified. Average tumor volume at day 57 was 50, 150, and 250 mm 3 in C and MPA-and N-EL-treated animals, respectively. The incidence of lymph node infiltration in the N-EL group was significantly different from that in the C group (P G 0.05, logistic analysis of variances performed using the GENMOD procedure in the SAS program). MPA, medroxyprogesterone acetate; N-EL, norgestrel; E 2, estradiol; C, control.
